This is the protocol for a review and there is no abstract. The objectives are as follows:
To summarise the evidence from randomised controlled trials for the effectiveness and safety of DMARDs in the treatment of juvenile-onset systemic lupus erythematosus, specifically:
To quantify the effects of DMARDs on disease activity, health related quality of life, risk of permanent organ damage and steroid dose.
To determine what serious adverse events are associated with DMARDs (using evidence from randomised controlled trials only).
To report on the tolerability of DMARDs.
If you can't find a tool you're looking for, please click the link at the top of the page to "Go to old article view". Alternatively, view our Knowledge Base articles for additional help. Your feedback is important to us, so please let us know if you have comments or ideas for improvement.